Fidaxomicin more cost effective than vancomycin in patients with cancer infected with clostridium difficile
the ONA take:
According to new research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), patients with cancer who become infected with clostridium dificile would save about €5,600 per patient if treated with fidaxomicin compared with vancomycin, the current standard of care.
Clostridium dificile infection (CDI) can often present in patients received chemotherapy. In addition, those with solid cancers can be more susceptible to CDI than those with liquid tumors due to longer hospital admissions and increased antibiotic exposure and anti-cancer agents. When antibiotics alter a patient's gut flora and destroy many bacteria that live in the gut, clostridium dificile is given the chance to multiply and cause infection, thus causing diarrhea requiring antibiotics with gram-positive anaerobic coverage.
The most common agents used to treat CDI are metronidazole, oral vancomycin, and fidaxomicin, but treatment depends on severity of the infection. Multiple courses of oral vancomycin can be expensive for patients, and this decision-tree analysis demonstrates that fidaxomicin for the treatment of CDI in patients with cancer can reduce healthcare spending while maintaining effectiveness compared with vancomycin.
Those infected with clostridium dificile would save about €5,600 per patient if treated with fidaxomicin.
New data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014) show that overall treatment costs for cancer patients with clostridium difficile infection (CDI), based on a decision tree analysis, are lower with fidaxomicin compared to current standard of care, vancomycin, resulting in a potential cost saving of €5,600 per patient.
Patients who have received chemotherapy and those with solid tumours can be particularly susceptible to CDI due to their long hospital stays and exposure to many antibiotics and chemotherapeutic agents. These patients are also prone to recurrent episodes of CDI.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations
- Parental Self-persuasion in Low-Income Groups Improves HPV Vaccination Rates
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions
- Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|